Upstream Bio Profitability Analysis

UPB Stock   27.07  0.08  0.29%   
Considering Upstream Bio's profitability and operating efficiency indicators, Upstream Bio may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in February. Profitability indicators assess Upstream Bio's ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-56.5 M
Current Value
-59.4 M
Quarterly Volatility
14.2 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Upstream Bio's Price To Sales Ratio is projected to decrease significantly based on the last few years of reporting. The current year's EV To Sales is expected to grow to 436.22, whereas Days Sales Outstanding is forecasted to decline to 91.20. At present, Upstream Bio's Net Interest Income is projected to increase significantly based on the last few years of reporting. The current year's Interest Income is expected to grow to about 14.6 M, whereas Accumulated Other Comprehensive Income is projected to grow to (21.4 K). As of January 4, 2026, Gross Profit is expected to decline to about 2.2 M. In addition to that, Pretax Profit Margin is expected to decline to -32
For Upstream Bio profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Upstream Bio to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Upstream Bio utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Upstream Bio's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Upstream Bio over time as well as its relative position and ranking within its peers.
Check out World Market Map.
For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.The next projected EPS of Upstream Bio is estimated to be -0.7 with future projections ranging from a low of -0.7425 to a high of -0.629275. Upstream Bio's most recent 12-month trailing earnings per share (EPS TTM) is at -6.4. Please be aware that the consensus of earnings estimates for Upstream Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Covid
Upstream Bio is projected to generate -0.7 in earnings per share on the 31st of December 2025. Upstream Bio earnings estimates show analyst consensus about projected Upstream Bio EPS (Earning Per Share). It derives the highest and the lowest estimates based on Upstream Bio's historical volatility. Many public companies, such as Upstream Bio, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Upstream Bio's earnings estimates, investors can diagnose different trends across Upstream Bio's analyst sentiment over time as well as compare current estimates against different timeframes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Upstream Bio. If investors know Upstream will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Upstream Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(6.40)
Revenue Per Share
0.054
Quarterly Revenue Growth
0.125
Return On Assets
(0.28)
Return On Equity
(0.41)
The market value of Upstream Bio is measured differently than its book value, which is the value of Upstream that is recorded on the company's balance sheet. Investors also form their own opinion of Upstream Bio's value that differs from its market value or its book value, called intrinsic value, which is Upstream Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Upstream Bio's market value can be influenced by many factors that don't directly affect Upstream Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Upstream Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Upstream Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Upstream Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Upstream Bio Return On Asset vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Upstream Bio's current stock value. Our valuation model uses many indicators to compare Upstream Bio value to that of its competitors to determine the firm's financial worth.
Upstream Bio is rated third in return on equity category among its peers. It is rated fourth in return on asset category among its peers . At present, Upstream Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Upstream Bio's earnings, one of the primary drivers of an investment's value.

Upstream Return On Asset vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Upstream Bio

Return On Equity

 = 

Net Income

Total Equity

 = 
-0.41
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Upstream Bio

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.28
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Upstream Return On Asset Comparison

Upstream Bio is currently under evaluation in return on asset category among its peers.

Upstream Bio Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Upstream Bio, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Upstream Bio will eventually generate negative long term returns. The profitability progress is the general direction of Upstream Bio's change in net profit over the period of time. It can combine multiple indicators of Upstream Bio, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-22.5 K-21.4 K
Net Interest Income13.9 M14.6 M
Interest Income13.9 M14.6 M
Operating Income-70 M-73.5 M
Net Loss-56.5 M-59.4 M
Income Before Tax-56.5 M-59.4 M
Total Other Income Expense Net17.2 M12.7 M
Net Loss-56.5 M-59.4 M
Net Loss(1.41)(1.48)
Income Quality 0.85  0.96 

Upstream Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Upstream Bio. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Upstream Bio position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Upstream Bio's important profitability drivers and their relationship over time.

Upstream Bio Profitability Trends

Upstream Bio profitability trend refers to the progression of profit or loss within a business. An upward trend means that Upstream Bio's profit has generally increased over time, and a downward profitability trend means profits are declining. Recognizing problems early in profitability trends allows investors to address revenue and cost issues in advance. Investors and analysts usually monitor three types of profitability trends: gross, operating, and net. Gross profit is the difference between revenue and costs of goods sold. Operating profit is Upstream Bio's gross profit minus its overhead. After you account for other unusual revenue, expenses, and costs, you get net profit. Gross profit trends are often a good indicator of future profitability. If you have high gross profit margins, you have a better chance to cover overhead and make money.

Upstream Bio Profitability Drivers Correlations

One of the toughest challenges investors face today is learning how to quickly synthesize and read into endless financial statements and information provided by the company, SEC reporting, and various external parties. Understanding the correlation between Upstream Bio different financial indicators related to revenue and profit generation helps investors identify and prioritize their investing strategies towards Upstream Bio in a much-optimized way. Analyzing correlations between profit drivers that are directly associated with dollar figures is the most effective way to break down Upstream Bio's future profitability.

Upstream Bio Earnings Estimation Breakdown

The calculation of Upstream Bio's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Upstream Bio is estimated to be -0.7 with the future projection ranging from a low of -0.7425 to a high of -0.629275. Please be aware that this consensus of annual earnings estimates for Upstream Bio is based on EPS before non-recurring items and includes expenses related to employee stock options.
Last Reported EPS
-0.63
-0.74
Lowest
Expected EPS
-0.7
-0.63
Highest

Upstream Bio Earnings Projection Consensus

Suppose the current estimates of Upstream Bio's value are higher than the current market price of the Upstream Bio stock. In this case, investors may conclude that Upstream Bio is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Upstream Bio's stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyLast Reported EPSEstimated EPS for 31st of December 2025Current EPS (TTM)
877.78%
-0.63
-0.7
-6.4

Upstream Bio Earnings History

Earnings estimate consensus by Upstream Bio analysts from Wall Street is used by the market to judge Upstream Bio's stock performance. Investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only Upstream Bio's upcoming profit reports and earnings-per-share forecasts but also comparing them to our different valuation methods.

Upstream Bio Quarterly Gross Profit

652,000

As of January 4, 2026, Retained Earnings is expected to decline to about (180.3 M). In addition to that, Earnings Yield is expected to decline to -0.09 As of January 4, 2026, Common Stock Shares Outstanding is expected to decline to about 45.5 M.
Hype
Prediction
LowEstimatedHigh
22.7627.0731.38
Details
Intrinsic
Valuation
LowRealHigh
21.5625.8730.18
Details
Naive
Forecast
LowNextHigh
21.6825.9830.29
Details
4 Analysts
Consensus
LowTargetHigh
45.2749.7555.22
Details
Note that many institutional investors and large investment bankers can move markets due to the volume of Upstream assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards Upstream Bio. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving Upstream Bio's stock price in the short term.

Upstream Bio Earnings per Share Projection vs Actual

Actual Earning per Share of Upstream Bio refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Upstream Bio predict the company's earnings will be in the future. The higher the earnings per share of Upstream Bio, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

Upstream Bio Estimated Months Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as Upstream Bio, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Upstream Bio should always be considered in relation to other companies to make a more educated investment decision.

Upstream Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact Upstream Bio's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2025-11-05
2025-09-30-0.77-0.630.1418 
2025-08-06
2025-06-30-0.61-0.74-0.1321 
2025-05-06
2025-03-31-0.48-0.51-0.03
2025-03-12
2024-12-31-0.5403-0.410.130324 
2024-11-07
2024-09-30-3.65-6.96-3.3190 
2024-08-28
2024-06-300-11.18-11.18

Use Upstream Bio in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Upstream Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Upstream Bio will appreciate offsetting losses from the drop in the long position's value.

Upstream Bio Pair Trading

Upstream Bio Pair Trading Analysis

The ability to find closely correlated positions to Upstream Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Upstream Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Upstream Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Upstream Bio to buy it.
The correlation of Upstream Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Upstream Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Upstream Bio moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Upstream Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Upstream Bio position

In addition to having Upstream Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Blockchain Thematic Idea Now

Blockchain
Blockchain Theme
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 29 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Upstream Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Upstream Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Upstream Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Upstream Bio Stock:
Check out World Market Map.
For information on how to trade Upstream Stock refer to our How to Trade Upstream Stock guide.
You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
To fully project Upstream Bio's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Upstream Bio at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Upstream Bio's income statement, its balance sheet, and the statement of cash flows.
Potential Upstream Bio investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Upstream Bio investors may work on each financial statement separately, they are all related. The changes in Upstream Bio's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Upstream Bio's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.